The CANTOS trial, a landmark randomized controlled clinical trial, found that canakinumab, a monoclonal antibody directed against interleukin-1β, significantly reduced the risk of MACE in patients with a history of myocardial infarction and elevated levels of high-sensitivity C-reactive protein (hs-CRP). Here, CRP is linked to myocardial infarction.